Akers Biosciences, Inc. Agreement with GNYHA for PIFA Heparin PF4 Test (1677S)
December 19 2016 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 1677S
Akers Biosciences, Inc.
19 December 2016
19 December 2016
This announcement contains inside information
Akers Biosciences, Inc.
3-year Agreement with Greater New York Hospital Association for
Heparin PF4 Rapid Test
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, has signed a three-year agreement with the Greater
New York Hospital Association (GNYHA) to introduce the Company's
flagship rapid tests for heparin-induced thrombocytopenia ("HIT")
across GNYHA's network of over 300 member hospitals.
Founded in 1904, GNYHA is a trade and group purchasing
association representing a large number of hospitals and healthcare
systems in New York, New Jersey, Connecticut, and Rhode Island;
including some of the most prestigious healthcare organizations in
the United States.
Akers Bio's flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS
PF4 tests were designed to quickly determine at - or near - the
point-of-care if a patient being treated with the widely used blood
thinner heparin may be developing HIT. This clinical syndrome
reverses heparin's intended therapeutic effect and transforms it
into a clotting agent. Patients suffering HIT are at risk of
developing limb- and life-threatening complications, so the timely
test result provided by the Company's Heparin/PF4 devices is
paramount to effective and cost-efficient clinical decision
making.
Akers Bio believes its rapid tests have the capacity to provide
dramatic cost savings for hospitals when compared to traditional
testing methodologies for detecting HIT. The Company estimates that
a typical hospital can save $0.5 - $1 million per annum in testing,
pharmacy, and clinical monitoring costs.
Under the terms of the agreement, Akers Bio's flagship PIFA
Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests will be evaluated
at two significant GNYHA member hospitals, Kaleida Health - which
is the largest provider in Western New York - and Kingsbrook Jewish
Medical Center - a major teaching hospital in Brooklyn. The outcome
of the evaluations will be shared with GNYHA's extensive member
network to which Akers Bio will, with GNYHA's support, begin
marketing the Company's tests.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented:
"Akers Bio is delighted to have signed a three-year agreement
with GNYHA, one of the premier group purchasing organizations in
the United States healthcare sector. Their membership includes a
diverse listing of prominent and large integrated delivery networks
(IDNs) and hospitals. Enhanced access to GNYHA's network has the
potential to dramatically increase domestic sales of our flagship
product.
"We look forward to working with GNYHA to introduce PIFA
Heparin/PF4 clinical diagnostic products that will improve
effectiveness, operational efficiency and profitable outcomes for
their members."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFFEFFAFMSEIE
(END) Dow Jones Newswires
December 19, 2016 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024